CD8A and neoplasm: Importantly, PCSK9 can reduce the expression of major histocompatibility complex (MHC) I protein on the surface of tumor cells, weaken T-cell receptor circulation and signal transmission, and inhibit the tumor infiltration and anti-tumor activity of CD8+ T cells [10,11].